/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Seres Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$16.94 0.0312(3.12%) MCRB at 09 Dec 2025 05:50 PM Biotechnology
Lowest Today 16.6
Highest Today 17.35
Today’s Open 16.85
Prev. Close 16.66
52 Week High 29.98
52 Week Low 6.53
Day’s Range: Low 16.6 High 17.35
52-Week Range: Low 6.53 High 29.98
1 day return -
1 Week return +3.0
1 month return +22.07
3 month return -7.4
6 month return +114.78
1 year return +1915.99
3 year return +161.87
5 year return -28.25
10 year return -

Institutional Holdings

Flagship Ventures Management, Inc. 13.20

Vanguard Group Inc 3.34

FMR Inc 3.07

Vanguard Total Stock Mkt Idx Inv 2.16

BlackRock Inc 1.16

Geode Capital Management, LLC 1.05

Marshall Wace Asset Management Ltd 1.04

Vontobel Holding Ltd. 0.92

Vanguard Institutional Extnd Mkt Idx Tr 0.88

LUX IM Global Medtech HX 0.55

Fidelity Extended Market Index 0.44

Charles Schwab Investment Management Inc 0.40

Schwab US Small-Cap ETF™ 0.40

State Street Corp 0.31

XTX Topco Ltd 0.26

Squarepoint Ops LLC 0.24

Fidelity VIP Growth Initial 0.23

Lion Point Capital, LP 0.19

Northern Trust Corp 0.17

iShares Micro-Cap ETF 0.17

Extended Equity Market Fund K 0.16

Fidelity Total Market Index 0.16

TANG CAPITAL MANAGEMENT LLC 0.16

Fidelity Growth Company Fund 0.15

Bridgeway Capital Management, LLC 0.14

Bridgeway Ultra-Small Company Market 0.14

Fidelity Advisor Equity Growth I 0.13

Susquehanna International Group, LLP 0.13

Fidelity Series Total Market Index 0.12

Spartan Extended Market Index Pool F 0.10

Northern Trust Extended Eq Market Idx 0.09

NT Ext Equity Mkt Idx Fd - L 0.09

Fidelity Growth Discovery 0.09

Morgan Stanley - Brokerage Accounts 0.09

UBS Group AG 0.09

Royal Bank of Canada 0.08

NT Ext Equity Mkt Idx Fd - NL 0.08

SBI Securities Co Ltd 0.04

Vanguard Instl Ttl Stck Mkt Idx Tr 0.04

NT Ext Eq Mkt Indx Fd DC Lend T3 0.02

Market Status

Strong Buy: 2

Buy: 0

Hold: 2

Sell: 1

Strong Sell: 0

Fundamentals

Market Cap 150.72 M

PB Ratio 3.4491

PE Ratio 18.9318

Enterprise Value 188.33 M

Total Assets 139.81 M

Volume 112841

Company Financials

Annual Revenue FY23:127236000 127.2M, FY22:7128000 7.1M, FY21:144927000 144.9M, FY20:33215000 33.2M, FY19:34505000 34.5M

Annual Profit FY23:null 0.0M, FY22:6124000 6.1M, FY21:143195000 143.2M, FY20:33215000 33.2M, FY19:34505000 34.5M

Annual Net worth FY23:-141272000 -141.3M, FY22:-253824000 -253.8M, FY21:-61496000 -61.5M, FY20:-86454000 -86.5M, FY19:-64244000 -64.2M

Quarterly Revenue Q3/2025:351000 0.4M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-13001000 -13.0M, Q2/2025:-1059000 -1.1M, Q1/2025:-3527000 -3.5M, Q3/2024:null 0.0M, Q2/2024:-1420000 -1.4M

Quarterly Net worth Q3/2025:8204000 8.2M, Q2/2025:-19855000 -19.9M, Q1/2025:32682000 32.7M, Q3/2024:88776000 88.8M, Q2/2024:-32869999 -32.9M

Fund house & investment objective

Company Information Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline programs include SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease; and SER-287 and SER-301, which are in clinical trials for the treatment of mild-to-moderate ulcerative colitis. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 103

Industry Biotechnology

CEO Mr. Thomas J. DesRosier Esq., J.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow